India Inc is set to double capex to US$ 850 billion by 2030, led by power, aviation, and green hydrogen, with top firms funding growth through strong balance sheets and policy tailwinds.

HSBC Mutual Fund (MF) remains optimistic about Indian equities, citing favourable valuations and a revival in growth momentum.

India’s digital public infrastructure, led by Unified Payments Interface (UPI) and Direct Benefit Transfer (DBT), has transformed financial inclusion and efficiency, drawing global acclaim as the ...

India’s agricultural output has risen 40% in the past decade, with 5.4% growth in Q4 FY25, reflecting self-sufficiency, export strength, and proactive government-farmer-scientist collaboration.

Prime Minister Mr. Narendra Modi marked 11 years of leadership, highlighting India’s rapid economic rise, inclusive governance, and transformative welfare initiatives for marginalised communities.

Uttar Pradesh aims to attract US$ 1.40 billion in private investment for a 1,472-acre Bulk Drug Pharma Park in Lalitpur, targeting self-reliance and job creation while also expanding medical ...

Shein and Reliance Retail plan to scale India’s supplier base from 150 to 1,000 within a year, launching India-made Shein apparel for domestic and global markets to diversify.

India’s Maternal Mortality Ratio fell from 130 to 80 per lakh live births (2014-2016 to 2021-2023) due to the Pradhan Mantri Surakshit Matritva Abhiyan and allied maternal health programmes.

India’s auto retail sales grew 5% in May, driven by rural demand, while passenger vehicle sales dropped 3% due to geopolitical tensions and financing challenges.

RBI cut the Cash Reserve Ratio by 1% in four tranches, freeing US$ 29.15 billion in liquidity for banks to boost lending, aiming to support economic growth and ease funding costs.

Union Minister of Consumer Affairs, Food, and Public Distribution, Mr. Pralhad Joshi, highlighted India’s rise as a global manufacturing hub, driven by youth talent, sustainability efforts, and policy ...

India’s pharmaceutical market grew 7.2% in May 2025, driven by price hikes and new launches, with chronic therapies and smaller segments like urology and antineoplastics seeing strong double-digit ...